STOCK TITAN

[SCHEDULE 13G/A] Editas Medicine, Inc. Amended Passive Investment Disclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed an amendment (Schedule 13G/A) reporting that it beneficially owns 0 shares of Editas Medicine common stock, representing 0% of the class. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership after internal reorganization.

The filing states The Vanguard Group beneficially owns 0 shares of Editas Medicine common stock and reports 0% ownership. The amendment cites an internal realignment on January 12, 2026

Cash‑flow treatment is not applicable; subsequent disclosures by Vanguard affiliates may show any separate beneficial positions. The current filing removes The Vanguard Group as an aggregated beneficial owner.

Amendment follows SEC Release No. 34-39538 disaggregation guidance.

The statement references reliance on SEC Release No. 34-39538 to report certain subsidiaries or business divisions separately after the January 12, 2026 realignment. It states those entities pursue the same investment strategies previously used.

This is an administrative ownership update; material investor impact depends on whether any affiliated entities report separate holdings in subsequent filings.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026
Editas Medicine Inc

NASDAQ:EDIT

View EDIT Stock Overview

EDIT Rankings

EDIT Latest News

EDIT Latest SEC Filings

EDIT Stock Data

227.06M
97.61M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
CAMBRIDGE